MiR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2

84Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Drug resistance is one of the leading causes of chemotherapy failure in cancer treatment. MicroRNAs (miRNAs or miRs) are short non-coding RNA molecules that post-transcriptionally regulate gene expression and play a critical role in diverse biological processes. In this study, we report that miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin. The expression of miR-503 was decreased in the cisplatin-resistant non-small cell lung cancer cells, A549/CDDP, compared with the parental A549 cells. The overexpression of miR-503 sensitized the A549/CDDP cells to cisplatin, whereas the inhibition of miR-503 in the A549 cells increased resistance to cisplatin. Mechanistically, miR-503 specifically targeted Bcl-2, an anti-apoptotic protein upregulated in the A549/CDDP cells. The ectopic expression of miR-503 reduced the Bcl-2 protein level and sensitized the A549/CDDP cells to cisplatin-induced apoptosis. Taken together, our results suggest that miR-503 regulates cell apoptosis, at least in part by targeting Bcl-2, and thus modulates the resistance of non-small cell lung cancer cells to cisplatin.

Cite

CITATION STYLE

APA

Qiu, T., Zhou, L., Wang, T., Xu, J., Wang, J., Chen, W., … Liu, P. (2013). MiR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. International Journal of Molecular Medicine, 32(3), 593–598. https://doi.org/10.3892/ijmm.2013.1439

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free